242 related articles for article (PubMed ID: 16752169)
21. Effects of a 3-year dietary intervention on age-related changes in triglyceride and apolipoprotein A-V levels in patients with impaired fasting glucose or new-onset type 2 diabetes as a function of the APOA5 -1131 T > C polymorphism.
Kim M; Chae JS; Kim M; Lee SH; Lee JH
Nutr J; 2014 Apr; 13():40. PubMed ID: 24775272
[TBL] [Abstract][Full Text] [Related]
22. Elevated levels of triglyceride and triglyceride-rich lipoprotein triglyceride induced by a high-carbohydrate diet is associated with polymorphisms of APOA5-1131T>C and APOC3-482C>T in Chinese healthy young adults.
Lin J; Fang DZ; Du J; Shigdar S; Xiao LY; Zhou XD; Duan W
Ann Nutr Metab; 2011; 58(2):150-7. PubMed ID: 21646779
[TBL] [Abstract][Full Text] [Related]
23. The APOA5 Trp19 allele is associated with metabolic syndrome via its association with plasma triglycerides.
Dallongeville J; Cottel D; Wagner A; Ducimetière P; Ruidavets JB; Arveiler D; Bingham A; Ferrières J; Amouyel P; Meirhaeghe A
BMC Med Genet; 2008 Sep; 9():84. PubMed ID: 18789138
[TBL] [Abstract][Full Text] [Related]
24. APOC3/A5 haplotypes, lipid levels, and risk of myocardial infarction in the Central Valley of Costa Rica.
Ruiz-Narváez EA; Yang Y; Nakanishi Y; Kirchdorfer J; Campos H
J Lipid Res; 2005 Dec; 46(12):2605-13. PubMed ID: 16192625
[TBL] [Abstract][Full Text] [Related]
25. The effect of atorvastatin on postprandial lipaemia in overweight or obese women homozygous for apo E3.
Vansant G; Mertens A; Muls E
Acta Cardiol; 2001 Jun; 56(3):149-54. PubMed ID: 11471927
[TBL] [Abstract][Full Text] [Related]
26. Impact of APOA5/A4/C3 genetic polymorphisms on lipid variables and cardiovascular disease risk in French men.
Dallongeville J; Cottel D; Montaye M; Codron V; Amouyel P; Helbecque N
Int J Cardiol; 2006 Jan; 106(2):152-6. PubMed ID: 16321685
[TBL] [Abstract][Full Text] [Related]
27. Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein.
Kappelle PJ; Zwang L; Huisman MV; Banga JD; Sluiter WJ; Dallinga-Thie GM; Dullaart RP
Expert Opin Ther Targets; 2009 Jul; 13(7):743-51. PubMed ID: 19505224
[TBL] [Abstract][Full Text] [Related]
28. Plasma fibronectin level and its relationships with lipids, lipoproteins and C-reactive protein in patients with dyslipidaemia during lipid-lowering therapy.
Orem C; Orem A; Calapoğlu M; Baykan M; Uydu HA; Erdöl C
Acta Cardiol; 2002 Dec; 57(6):421-5. PubMed ID: 12542120
[TBL] [Abstract][Full Text] [Related]
29. Association of APOA5 c.553G>T polymorphism with type 2 diabetes mellitus in a Chinese population.
Zhai G; Wen P; Guo L; Chen L
Clin Chem Lab Med; 2006; 44(11):1313-6. PubMed ID: 17087641
[TBL] [Abstract][Full Text] [Related]
30. Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy.
Arnedo M; Taffé P; Sahli R; Furrer H; Hirschel B; Elzi L; Weber R; Vernazza P; Bernasconi E; Darioli R; Bergmann S; Beckmann JS; Telenti A; Tarr PE;
Pharmacogenet Genomics; 2007 Sep; 17(9):755-64. PubMed ID: 17700364
[TBL] [Abstract][Full Text] [Related]
31. The single nucleotide polymorphism -1131T>C in the apolipoprotein A5 (APOA5) gene is associated with elevated triglycerides in patients with hyperlipidemia.
Evans D; Buchwald A; Beil FU
J Mol Med (Berl); 2003 Oct; 81(10):645-54. PubMed ID: 12937897
[TBL] [Abstract][Full Text] [Related]
32. Association between plasma lipid parameters and APOC3 genotypes in Brazilian subjects: effect of gender, smoking and APOE genotypes.
Fiegenbaum M; de Andrade FM; Hutz MH
Clin Chim Acta; 2007 May; 380(1-2):175-81. PubMed ID: 17367769
[TBL] [Abstract][Full Text] [Related]
33. Consumption of whole grains and legumes modulates the genetic effect of the APOA5 -1131C variant on changes in triglyceride and apolipoprotein A-V concentrations in patients with impaired fasting glucose or newly diagnosed type 2 diabetes.
Kang R; Kim M; Chae JS; Lee SH; Lee JH
Trials; 2014 Apr; 15():100. PubMed ID: 24690159
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.
Bakker-Arkema RG; Davidson MH; Goldstein RJ; Davignon J; Isaacsohn JL; Weiss SR; Keilson LM; Brown WV; Miller VT; Shurzinske LJ; Black DM
JAMA; 1996 Jan; 275(2):128-33. PubMed ID: 8531308
[TBL] [Abstract][Full Text] [Related]
35. Emerging evidences for the opposite role of apolipoprotein C3 and apolipoprotein A5 in lipid metabolism and coronary artery disease.
Dai W; Zhang Z; Yao C; Zhao S
Lipids Health Dis; 2019 Dec; 18(1):220. PubMed ID: 31836003
[TBL] [Abstract][Full Text] [Related]
36. Influence of atorvastatin on apolipoprotein E and AI kinetics in patients with type 2 diabetes.
Bach-Ngohou K; Ouguerram K; Frénais R; Maugère P; Ripolles-Piquer B; Zaïr Y; Krempf M; Bard JM
J Pharmacol Exp Ther; 2005 Oct; 315(1):363-9. PubMed ID: 16014756
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Jones PH; Cusi K; Davidson MH; Kelly MT; Setze CM; Thakker K; Sleep DJ; Stolzenbach JC
Am J Cardiovasc Drugs; 2010; 10(2):73-84. PubMed ID: 20136164
[TBL] [Abstract][Full Text] [Related]
38. Modulation of phenotypic expression of APOA5 Q97X and L242P mutations.
Charrière S; Cugnet C; Guitard M; Bernard S; Groisne L; Charcosset M; Pruneta-Deloche V; Merlin M; Billon S; Delay M; Sassolas A; Moulin P; Marçais C
Atherosclerosis; 2009 Nov; 207(1):150-6. PubMed ID: 19447388
[TBL] [Abstract][Full Text] [Related]
39. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.
Hogue JC; Lamarche B; Deshaies Y; Tremblay AJ; Bergeron J; Gagné C; Couture P
Metabolism; 2008 Feb; 57(2):246-54. PubMed ID: 18191056
[TBL] [Abstract][Full Text] [Related]
40. Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate: the genetics of lipid-lowering drugs and diet network study.
Liu Y; Ordovas JM; Gao G; Province M; Straka RJ; Tsai MY; Lai CQ; Zhang K; Borecki I; Hixson JE; Allison DB; Arnett DK
Pharmacogenet Genomics; 2009 Feb; 19(2):161-9. PubMed ID: 19057464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
